OTCMKTS:EMIS Emisphere Technologies (EMIS) Stock Price, News & Analysis $7.81 0.00 (0.00%) As of 12/9/2020 Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Emisphere Technologies Stock (OTCMKTS:EMIS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Emisphere Technologies alerts:Sign Up Key Stats Today's Range$7.81▼$7.8150-Day Range$7.81▼$7.8152-Week Range$4.06▼$9.16VolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Emisphere Technologies, Inc. operates as a commercial stage pharmaceutical and drug delivery company in the United States. The company offers oral Eligen B12 Rx, an oral formulation prescription medical food for use by B12 deficient individuals. It is also developing GLP-1, which is in Phase III clinical trial for the treatment of type 2 diabetes and related conditions. The company's preclinical programs focus on the development of oral formulations for the treatment of diabetes; and products in the areas of cardiovascular, appetite suppression, and pain, as well as in the development and expansion of nutritional supplement products. It has license agreements with Novo Nordisk A/S to develop and commercialize oral formulations of GLP-1 receptor agonists in combination with Emisphere carriers, as well as to develop and commercialize oral formulations of Novo Nordisk's insulin using the company's Eligen Technology. The company was formerly known as Clinical Technologies Associates, Inc. and changed its name to Emisphere Technologies, Inc. in 1991. Emisphere Technologies, Inc. was founded in 1986 and is based in Roseland, New Jersey. Read More Receive EMIS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Emisphere Technologies and its competitors with MarketBeat's FREE daily newsletter. Email Address EMIS Stock News HeadlinesEarnings call: SWK Holdings focuses on life science finance growthMay 18, 2024 | au.investing.comExco Technologies Limited (XTC.TO)March 3, 2024 | ca.finance.yahoo.comMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.August 10 at 2:00 AM | Brownstone Research (Ad)Insulin pill could free diabetics from jabsDecember 11, 2023 | dailymail.co.ukSHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in Emisphere Technologies, Inc. with Losses of $100,000 to Contact the FirmNovember 19, 2023 | barrons.comEMIS INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Emisphere Technologies, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!October 23, 2023 | businesswire.comEntwistle & Cappucci LLP Files a Securities Class Action Complaint Against Emisphere Technologies, Inc.October 5, 2023 | benzinga.comBuccal Drug Delivery System Global Market Report 2023May 8, 2023 | finance.yahoo.comSee More Headlines EMIS Stock Analysis - Frequently Asked Questions How have EMIS shares performed this year? Emisphere Technologies' stock was trading at $7.81 on January 1st, 2025. Since then, EMIS shares have increased by 0.0% and is now trading at $7.81. How were Emisphere Technologies' earnings last quarter? Emisphere Technologies Inc. (OTCMKTS:EMIS) announced its earnings results on Friday, May, 12th. The company reported $0.04 earnings per share (EPS) for the quarter. The firm had revenue of $0.22 million for the quarter. How do I buy shares of Emisphere Technologies? Shares of EMIS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Emisphere Technologies own? Based on aggregate information from My MarketBeat watchlists, some other companies that Emisphere Technologies investors own include Novo Nordisk A/S (NVO), Fulcrum Therapeutics (FULC), VIVUS (VVUS), Aldeyra Therapeutics (ALDX), Allena Pharmaceuticals (ALNA) and Capricor Therapeutics (CAPR). Company Calendar Last Earnings5/12/2017Today8/10/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry MED - DRUGS Sub-IndustryN/A Current SymbolOTCMKTS:EMIS CIK805326 Webwww.emisphere.com Phone973-532-8000Fax973-422-0125Employees6Year Founded1986Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Social Links Analysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (OTCMKTS:EMIS) was last updated on 8/10/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGreen Light for These StocksGuess Who Washington Will Partner With Next? The U.S. government just made a bold $400 million move... beco...Stansberry Research | Sponsored"Death Spiral" Threatening Your SavingsThe "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Emisphere Technologies Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Emisphere Technologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.